



## **Aurobindo receives USFDA Approval for Cefpodoxime proxetil Tablets**

Aurobindo Pharma Limited is pleased to announce that the USFDA has approved one more from its cephalosporin stable and again from its third generation breed. Cefpodoxime proxetil Tablets in the strengths of 100mg and 200mg has been approved. This is the 7<sup>th</sup> cephalosporin approval for Aurobindo. With this the company consolidates itself further in cephalosporin market. Cefpodoxime is the generic version of Pharmacia Upjohn's Vantin.

Cefpodoxime Proxetil is mostly used to treat Acute otitis media, community acquired Pneumoniae, Uncomplicated Urinary tract infections and also skin infections.

Aurobindo is the proven leader in this segment/product range in several markets in the world. This would be a niche opportunity for the company as there are limited number of players in the segment.

USFDA has also confirmed its approval for Cefpodoxime proxetil for oral suspension in the strengths of 50mg/5ml and 100mg/5ml.

### **About Aurobindo Pharma Limited:**

Aurobindo Pharma Limited ([www.aurobindo.com](http://www.aurobindo.com)), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company has received approvals for most of the targeted API and formulation facilities from leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics. The formulation portfolio is built on six technology platforms such as immediate release generics, SR/CR generics, Orally disintegrating/Mouth dissolving generics, Combination products, Sterile/Lyophilized generics and Liquids/Dry syrups. Aurobindo has filed over 100 DMFs and 79 ANDAs for the USA market alone in addition to filings in other countries. The pace of filings is matched by rapid product approvals from various markets. Till date Aurobindo received 40 ANDA approvals (both final and tentative) from US alone. Aurobindo operates in over 100 countries and markets over 180 APIs and 250 formulations